Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL969838 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPTPOLBUSP30MEN1 | |
| SCHEMBL895391 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2MAPTPOLBUSP30MEN1 | |
| SCHEMBL2847700 | 0.90 | HPGD (0.40) | SMN1; SMN2GAANPC1RAB9AALDH1A1 | |
| SCHEMBL971781 | 0.90 | HPGD (0.40) | SMN1; SMN2GAANPC1RAB9AALDH1A1 | |
| SCHEMBL3322339 | 0.90 | HPGD (0.40) | SMN1; SMN2GAANPC1RAB9AALDH1A1 | |
| SCHEMBL2213404 | 0.90 | MAPT (0.38) | SMN1; SMN2MAPTPOLBMEN1KMT2A | |
| SCHEMBL3713407 | 0.86 | — | — | |
| SCHEMBL13058330 | 0.85 | SMN1; SMN2 (0.37) | SMN1; SMN2MAPTPOLBUSP30MEN1 | |
| SCHEMBL1935734 | 0.82 | BCHE (0.42) | SMN1; SMN2MAPTUSP30MEN1KMT2A | |
| SCHEMBL389962 | 0.80 | HPGD (0.54) | SMN1; SMN2MAPTUSP30MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024057013-A1 | NLRP3 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2023-01-26 | — | — | US | disclosed |
| WO-2021071806-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-2417124-B1 | Serotonin and norepinephrine reuptake inhibitor | LILLY CO ELI (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8173821-B2 | Serotonin and norepinephrine reuptake inhibitor | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2417124-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | Eli Lilly and Company (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117979-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, TPH1 | SMN1; SMN2 640/4885MAPT 450/4885POLB 1485/4885 |
| US-20230023559-A1 | ARYLMETHYLENE HETEROCYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNJ2, KCNA3, KCNH3 | SMN1; SMN2 1712/4885MAPT 3809/4885POLB 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.